NCT00309478View on ClinicalTrials.gov

Randomized Study Comparing CMF and Goserelin + Tamoxifen in Premenopausal Receptor-positive Patients

PHASE3CompletedINTERVENTIONAL

Enrollment

1,099

Participants

Timeline

Start Date

December 31, 1990

Primary Completion Date

June 30, 2004

Study Completion Date

June 30, 2004

Conditions

Early-stage Breast Cancer

Interventions

DRUG

Cyclophosphamide

Cyclophosphamide 600mg/m2

DRUG

Methotrexate

Methotrexate 40mg/m2

DRUG

Fluorouracil implant

Fluorouracil 600mg/m2

DRUG

Goserelin

Zoladex 3.6mg/28 days for 3 years

DRUG

Tamoxifen

Nolvadex 20mg/day for 5 years

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

AstraZeneca

INDUSTRY

lead

Austrian Breast & Colorectal Cancer Study Group

NETWORK